-transparent.png){kind=logo}
Autoimmune MRL/1 mice were treated with a recently developed substance with immunomodulating properties, LS-2616. Treatment was initiated at the age of 8 weeks, before the onset of clinically apparent disease, and at 16 weeks of age, after development of established lupus disease. Beneficial therapeutic effects were obtained, even when LS-2616 was administered at the lowest dose tested (1 mg/mouse/week) to 16-week-old mice. The effects of LS-2616 on longevity, as well as on development of lymphadenopathy, splenomegaly, glomerulonephritis, and vasculitis, were pronounced and were comparable with those of cyclophosphamide. The results obtained suggest a potential role for LS-2616 in the treatment of autoimmune disease in humans.
A Tarkowski, and
K Gunnarsson, and
L A Nilsson, and
L Lindholm, and
T Stålhandske
January 1988,
Cancer detection and prevention,
A Tarkowski, and
K Gunnarsson, and
L A Nilsson, and
L Lindholm, and
T Stålhandske
June 1985,
Journal of immunology (Baltimore, Md. : 1950),
A Tarkowski, and
K Gunnarsson, and
L A Nilsson, and
L Lindholm, and
T Stålhandske
January 1994,
World journal of surgery,
A Tarkowski, and
K Gunnarsson, and
L A Nilsson, and
L Lindholm, and
T Stålhandske
May 1989,
Journal of immunology (Baltimore, Md. : 1950),
A Tarkowski, and
K Gunnarsson, and
L A Nilsson, and
L Lindholm, and
T Stålhandske
February 1989,
Transplantation,
A Tarkowski, and
K Gunnarsson, and
L A Nilsson, and
L Lindholm, and
T Stålhandske
June 1986,
Cancer research,
A Tarkowski, and
K Gunnarsson, and
L A Nilsson, and
L Lindholm, and
T Stålhandske
June 1989,
Agents and actions,
A Tarkowski, and
K Gunnarsson, and
L A Nilsson, and
L Lindholm, and
T Stålhandske
April 1986,
Immunopharmacology,
A Tarkowski, and
K Gunnarsson, and
L A Nilsson, and
L Lindholm, and
T Stålhandske
December 1988,
Ryumachi. [Rheumatism],
A Tarkowski, and
K Gunnarsson, and
L A Nilsson, and
L Lindholm, and
T Stålhandske
January 1989,
Toxicologic pathology,
